Mira Pharmaceuticals Inc (MIRA)

Jun 18, 2025

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology - Knoxville News Sentinel

Jun 18, 2025

Jun 18, 2025

MIRA Pharmaceuticals’ ketamine analog accepted for publication By Investing.com - Investing.com Nigeria

Jun 18, 2025

Jun 18, 2025

Breakthrough Ketamine Alternative Passes Key Scientific Review: Phase 2 Trial Coming - Stock Titan

Jun 18, 2025

Jun 17, 2025

EON Resources Inc. Announcement - The Oklahoman

Jun 17, 2025

Jun 17, 2025

MIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology Journal - TipRanks

Jun 17, 2025

Jun 14, 2025

Two Sigma Investments LP Buys Shares of 24,317 MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World

Jun 14, 2025

Jun 10, 2025

Citadel Advisors LLC Makes New $112,000 Investment in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World

Jun 10, 2025

Jun 06, 2025

60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - USA Today

Jun 06, 2025

Jun 05, 2025

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Shares Acquired by Northern Trust Corp - Defense World

Jun 05, 2025

May 30, 2025

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times

May 30, 2025

May 28, 2025

MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | - GuruFocus

May 28, 2025

May 28, 2025

MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | MIRA Stock News - GuruFocus

May 28, 2025

May 28, 2025

MIRA Pharmaceuticals Joins BIO Convention for Strategic Opportunities - TipRanks

May 28, 2025

May 28, 2025

MIRA's Novel Pain Drug Shows Promise: Phase 1 Success Leads to Phase 2 Plans as Acquisition Nears - Stock Titan

May 28, 2025

May 28, 2025

MIRA Pharmaceuticals announces clinical progress and acquisition update - Investing.com

May 28, 2025

May 28, 2025

MIRA Pharmaceuticals announces clinical progress and acquisition update By Investing.com - Investing.com Nigeria

May 28, 2025

May 25, 2025

MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN

May 25, 2025

May 21, 2025

MIRA Pharmaceuticals appoints new CFO - Investing.com Australia

May 21, 2025

May 21, 2025

MIRA Pharmaceuticals Appoints New Chief Financial Officer - TipRanks

May 21, 2025

May 21, 2025

MIRA Pharmaceuticals appoints new CFO By Investing.com - Investing.com UK

May 21, 2025

May 11, 2025

MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong - MSN

May 11, 2025

May 11, 2025

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com

May 11, 2025

May 10, 2025

MIRA Pharmaceuticals (MIRA) Projected to Post Earnings on Monday - Defense World

May 10, 2025

May 09, 2025

Why Mira Pharmaceuticals Inc (NASDAQ: MIRA) Is A Great Stock Pick For Momentum Investors - Stocksregister

May 09, 2025

May 09, 2025

MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong By Stocktwits - Investing.com India

May 09, 2025

May 08, 2025

MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60M - TipRanks

May 08, 2025

May 08, 2025

MIRA Pharmaceuticals to acquire SKNY in strategic move - Investing.com

May 08, 2025

May 08, 2025

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review - Corsicana Daily Sun

May 08, 2025

May 08, 2025

EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Benzinga

May 08, 2025

May 08, 2025

Renaissance Technologies LLC Takes Position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World

May 08, 2025

May 06, 2025

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity - The Joplin Globe

May 06, 2025

May 06, 2025

MIRA Achieves Positive Safety Results in Neurotoxicity Study | M - GuruFocus

May 06, 2025

May 06, 2025

EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study - AOL.com

May 06, 2025

May 06, 2025

MIRA Pharmaceuticals reports safe profile for Ketamir-2 - Investing.com

May 06, 2025

May 06, 2025

MIRA Pharmaceuticals reports safe profile for Ketamir-2 By Investing.com - Investing.com UK

May 06, 2025

May 06, 2025

MIRA Pharmaceuticals Completes Key Neurotoxicity Study for Ketamir-2 - TipRanks

May 06, 2025

May 06, 2025

Breakthrough: New Drug Outperforms Ketamine in FDA Brain Safety StudyZero Toxicity Detected - Stock Titan

May 06, 2025

May 03, 2025

Pharmaceutical Stock Jumps After Key Trial Findings - MSN

May 03, 2025

May 03, 2025

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April - Defense World

May 03, 2025

Apr 24, 2025

Mira Pharmaceuticals Inc [MIRA] moved up 7.08: Why It’s Important - dbtnews.com

Apr 24, 2025

Apr 24, 2025

Financial Metrics Unveiled: Mira Pharmaceuticals Inc (MIRA)’s Key Ratios in the Spotlight - DWinneX

Apr 24, 2025

Apr 23, 2025

MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN

Apr 23, 2025

Apr 23, 2025

Mira Pharmaceuticals announces key drug development milestone By Investing.com - Investing.com Canada

Apr 23, 2025

Apr 23, 2025

Mira Pharmaceuticals announces key drug development milestone - Investing.com Australia

Apr 23, 2025

Apr 23, 2025

MIRA Pharmaceuticals (MIRA) Advances Ketamir-2 Formulations in P - GuruFocus

Apr 23, 2025